From Formulation to Commercial Manufacturing: Connect With Ascendia Pharmaceutical Solutions at AAPS PharmSci 360

Ascendia Pharmaceutical Solutions will exhibit at AAPS PharmSci 360 , taking place October 25-28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Attendees can meet the Ascendia Pharmaceutical Solutions team at Booth 1608 to discuss formulation development, pharmaceutical manufacturing, technology transfer, and strategies for advancing drug products from early development through commercialization.

AAPS PharmSci 360 brings together pharmaceutical scientists from industry, academia, government, and research organizations. The 2026 scientific program spans preclinical and translational sciences, bioanalytics, manufacturing and analytical characterization, and formulations and delivery.

Ascendia Pharmaceutical Solutions leadership will be available throughout the conference to host meetings with pharmaceutical and biotechnology companies. These discussions will focus on specific development priorities rather than broad capability overviews.

Sponsors can use time with Ascendia Pharmaceutical Solutions leadership to evaluate formulation challenges, development strategies, manufacturing requirements, and the steps needed to advance a program toward the next stage.

Direct access to executive leadership supports efficient, decision-oriented conversations aligned with sponsor priorities. Whether a program requires formulation optimization, clinical manufacturing support, or planning for commercial readiness, Ascendia Pharmaceutical Solutions can help define an appropriate development path.

Focus on Excipient Science at AAPS PharmSci 360

AAPS PharmSci 360 2026 will feature a new joint 2.5-day workshop with the United States Pharmacopeia (USP) focused on simple and complex excipients. The workshop will bring together USP scientists, industry experts and pharmaceutical development professionals for technical presentations, panel discussions and Q&A sessions addressing current challenges in excipient quality, composition and innovation.

Shaukat Ali, PhD, FAAPS, Vice Chair and member of the USP Excipient Chapters Committee, will participate alongside USP scientists and industry leaders throughout the workshop. Panel discussions will address excipient quality considerations for complex generics, development of the Excipient Composition General Chapter <1068>, and the role of emerging and novel excipients in future pharmaceutical development.

These sessions provide an opportunity to examine how excipient selection, characterization, and quality considerations can influence formulation development and drug product performance. Dr. Ali's participation further supports Ascendia Pharmaceutical Solutions' engagement with technical discussions relevant to complex formulation and drug development programs.

Pharmaceutical Development Support From Preformulation to Commercialization

Ascendia Pharmaceutical Solutions provides integrated pharmaceutical development and manufacturing services designed to support programs across the drug development lifecycle.

Services include preformulation studies, formulation development, analytical method development and validation, clinical trial material manufacturing, scale-up activities, technology transfer, and commercial manufacturing preparation.

This integrated approach allows development teams to address formulation, analytical, and manufacturing requirements as a connected program. Ascendia Pharmaceutical Solutions supports both small-molecule and biologics programs and applies specialized technologies to address complex formulation and drug delivery challenges.

Formulation Development for Complex Drug Products

Formulation challenges can affect solubility, dissolution, bioavailability, stability, and manufacturability. Ascendia Pharmaceutical Solutions develops customized formulations based on the characteristics and requirements of each drug product.

The company's technology portfolio includes NanoSol® for producing nanosized drug particles, AmorSol® for amorphous solid dispersions, EmulSol® for oil-in-water nano-emulsions, and LipidSol® for lipid nanoparticle applications. These technologies provide additional approaches for addressing formulation and drug delivery challenges that may limit the use of conventional development strategies.

Ascendia Pharmaceutical Solutions also supports development across multiple dosage forms and routes of administration, including oral solid dose, sterile injectables, and ophthalmic, among others.

Manufacturing Planning Across the Development Lifecycle

Manufacturing requirements change as a pharmaceutical program progresses from early development into clinical and commercial stages. Decisions made during formulation and process development can affect scale-up, technology transfer, manufacturing timelines, and future commercial readiness.

Ascendia Pharmaceutical Solutions supports these transitions through clinical trial material manufacturing, scale-up and technology transfer activities, as well as preparation for commercial manufacturing. The company manufactures cGMP clinical batches for injectable, tablet, and capsule dosage forms and provides analytical services to support formulation development.

Discussions at AAPS PharmSci 360 can help sponsors assess these requirements early and identify the development and manufacturing activities needed to support the next phase of a program.

Connect With Ascendia Pharmaceutical Solutions at AAPS PharmSci 360 2026

AAPS PharmSci 360 provides an opportunity for pharmaceutical and biotechnology companies to address current development challenges directly with Ascendia Pharmaceutical Solutions leadership.

Ascendia Pharmaceutical Solutions will be at Booth 1608 in New Orleans, October 25-28, 2026. Visitors should stop by the booth to learn more about an exclusive event Ascendia Pharmaceutical Solutions will be hosting during AAPS PharmSci 360 and how to participate. Sponsors evaluating formulation options, clinical manufacturing strategies, scale-up, technology transfer, or commercial manufacturing preparation can also schedule a meeting with the Ascendia Pharmaceutical Solutions team before the conference.

Contact Ascendia Pharmaceutical Solutions to schedule a meeting at Booth 1608 and discuss the development strategy, formulation challenges, and manufacturing requirements for the next stage of a pharmaceutical program.